Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Vemurafenib in Metastatic Melanoma
NCT01307397Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2011
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 44
01
Overview
A Phase 3 trial of vemurafenib in melanoma, sponsored by Roche. Started Mar 2011; status: completed.
02
Drugs
vemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01307397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01307397.